Be people-oriented and pursue mutual development
Established in 2011, RONGZHI FSENS PHARMACEUTICAL CO.,LTD. is a wholly-owned enterprise with a foreign juridical person. We are committed to the investment and construction in the fields of drug research and development, production, sales, medical services. RONGZHI FSENS advocates the "people-oriented" enterprise culture and brings together a group of high-quality professional management talents, skilled professional and technical talents and a united and enterprising marketing team. After several years of integrated development, it has initially grown into a brand enterprise with certain influence in the industry, continuously creating value for the society.
Advanced and high-end technology
The production base of RONGZHI FSENS is located at No. 4455, Jianguo Road, Meihekou City, Jilin Province, with a total investment of 120 million yuan, covering an area of 6,5000 square meters and a total construction area of 10087.36 square meters. The production base adopts imported automatic production equipment and advanced inspection and testing instruments. It successfully passed the new GMP verification in 2011, passed the GMP verification again in 2016, and wholly acquired JILIN CIFENG MEDICINE CO.,LTD in 2017. At present, it has 3 patents for invention, enjoying unique competitive advantages in the industry.（More details of the patents in Product Information Page）
Efficient, safe and healthy service
RONGZHI FSENS has a product with great scientific and technological content and market prospect - lienal polypeptide injection. As an immunomodulator with bidirectional immunomodulatory function, the product has been recognized by doctors and patients for its outstanding curative effect and excellent safety since its listing, and has been widely used in tumor, pneumology, surgery, ICU and other departments.
In the tide of rapid development of the pharmaceutical industry, RONGZHI FSENS has never stopped the pace of innovation and research and development. In the future, its product line will be greatly enriched. It plans to enter the forefront of the domestic pharmaceutical industry in 5 to 10 years and become an international and professional health industry group!
About Us
Company
